Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STADA Arzneimittel AG

https://www.stada.com/

Latest From STADA Arzneimittel AG

Stada Takes ViruProtect To Russia And Beyond

Germany's Stada has expanded its deal with Enymatica to take the latter's ViruProtect common cold brand into Russia, the CIS and beyond.

Deals OTC Devices

Thinking About Entering The EU CBD Market? Some Food For Thought

Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal. 

Wellness Dietary Supplements

Stada Strikes Deals With Lobsor And MediPharm

Stada's Britannia Pharmaceuticals has acquired Sweden's Lobsor and its Lecigon gel formulation which is already approved in the Nordics and combines levodopa, carbidopa and entacapone infused via a lightweight pump. Meanwhile, Stada has also formed an alliance with MediPharm Labs for medical cannabis.

Deals Value-Added Medicines

People On The Move: Appointments At Stada, BAH, Anefp And More

Stada hires BD and portfolio head; BAH welcomes back Lutz Boden; Anefp extends president's mandate; Ipsen gets BD chief from Merck; and Dr Kade appoints Sirius managing director.

Appointments Leadership
See All

Company Information

UsernamePublicRestriction

Register